Vaccine 25 (2007) [2960] [2961] [2962] Editorial New vaccines development, immunisation and immunotherapy Due to new modern sophisticated engineering technology, it is possible to accelerate the development of several novel and safe immunogenic vaccines. For example, a new, very effective conjugated meningococcal serogroup C vaccine was produced and introduced into the United Kingdom childhood immunisation programme, at the end of 1999. Rapid disappearance of confirmed cases of serogroup C meningococcal disease in vaccines was noted, suggesting the high efficacy of the vaccine. Meningococcal infection is the foremost infectious disease cause of death. Conjugated vaccines, being developed against meningococcal serogroups A, Y and W, are predicted to also be very effective. With the recent research progress in development of a vaccine against serogroup B meningococcus, the meningococcal diseases will be prevented, in the near future, by effective immunisation. Such a safe and highly immunogenic tailor-made vaccine against the Neisseria meningitidis serogroup B disease epidemic strain was developed with success to control the devastating group B meningococcal epidemic in New Zealand.
The seven-valent pneumococcal conjugate vaccine was first licensed in the United States in 2000, for the prevention of invasive pneumococcal disease (IPD), caused by the serotypes included in the vaccine. It is presently approved in 74 countries, and more than 100 million doses of vaccine have been distributed to date. Within 1 year of routine use in the US, incidence of vaccine-serotype invasive pneumococcal disease had fallen dramatically among children younger than 2 years. The most recent data available from the US demonstrates that vaccine-serotype IPD has declined by 96% among the age group recommended for vaccination. A need for new vaccines for endemic, pandemic, biodefence and traveller's is evident. These vaccines should be needle-free, single dose, temperature stable, and non-expensive. Some biotechs are developing such vaccines against cholera, typhoid fever, pandemic influenza, anthrax, plague, shigella and other diseases, as reported at the WCVII 2006.
Progress was made during recent years to develop vaccines against malaria. The Walter Reed Army Institute of Research with partners is developing a multi-stage and multiantigen vaccine to prevent Plasmodium falciparum malaria, and to limit the severity of the disease in patients that develop malaria. On the other hand, promising transmission blocking vaccines against two major species of malaria infecting humans, P. falciparum and P. vivax, are presently developed and tested in animals. At the National Institutes of Health, research is focusing on malaria vaccines designed to complement the natural immune response to parasites, by priming the immune system to subsequent boosting by natural infections, and by boosting immunity primed by infection.
Laboratories are currently actively involved in the development of new bacterial vaccines. Peptide and recombinant immunogens for protection against bacterial middle ear infection are reported as strong vaccine candidates against Moraxella catarrhalis, the most common causes of bacterial otitis in children. The development and registration of live attenuated vaccines for oral immunisation against bacterial enteric pathogens are underway. A single live oral recombinant vaccine has been licensed for immunisation of humans against cholera. The vaccine strain CVD103-HgR, from a wild Vibrio cholerae, has been shown to be very safe and highly immunogenic in humans, conferring protection against wild type challenge, after administration of a single vaccine dose. As tuberculosis is still causing around 3 million deaths per year, a considerable research effort is underway towards the development of a second generation subunit vaccine against Mycobacterium tuberculosis. Innovative approaches to TB vaccine, for better immunisation against TB, consists in stimulation of a T cell memory response that will enable a vigorous CD4+ and CD8+ effector T cell immune response. Vaccine development is focusing on improvements in BCG, which is now commonly used for initial immunisation of infants by WHO. Candidates for improvements and to replace current BCG consist of recombinant modified BCGs (rBCG), showing promise in animal TB disease testing. Another approach is to attenuate and modify Mtb for replacing BCG. Candidates for boosting the immune response after initial immunisation with BCG or rBCG include a number of recombinant Mtb proteins and fusion proteins, combined with new adjuvants, Mtb antigens vectored by viruses as a non-replicating adenovirus, modified vaccinia, and a bacterial phage delivery system, which has potential for oral administration. Several immuno-dominant molecules are experimented in subunit vaccines. An interesting polyprotein, Mtb72f, was found to be protective in animal models of tuberculosis that resembles human disease. The immunisation trials, with candidate Mtb72f vaccine, induced protection of cynomolgous monkeys. The DNA vaccination therapy of tuberculosis, experimented in different animal models, is also promising.
Regarding the protection against viral diseases, it should be pointed out that the influenza vaccine is immunogenic, highly cost-effective and cost-saving, but under-utilised throughout the world. Influenza infection results in considerable morbidity and mortality, especially in senior population, and in absenteeism at school and at work. The strategies to immunise populations against influenza viral infection, despite genetic changes in the virus, should be reconsidered with more adequate advertising on benefits to vaccinees, and on fast return of investment into vaccination campaigns. Recent data with intranasally administered trivalent, live, attenuated influenza vaccine, proved its effectiveness, efficacy and safety. The vaccine efficacy was 95% against lower respiratory infection and 96% against febrile illness. The new adjuvanted influenza vaccine, with novel adjuvants, demonstrated that the addition of MF59 adjuvant emulsion to subunit influenza vaccines enhances a high immune response in the elderly. The vaccine is well tolerated and safe. Also the DNA vaccination and RNA immunoprophylaxis eliciting protective immunity against influenza infection are investigated with genetic vaccine candidates. Mice vaccinated with liposome-encapsulated plasmid DNA, intranasally or intramuscularly, were fully protected, while naked DNA provided only partial protection. Immunoprophylaxis with polyriboinosinic-polyribocytidylic dsRNA, encapsulated in liposomes, also induced protection against virus challenge in mice. These approaches merit full attention for the eventual prevention in the future of respiratory influenza illness, as alternatives to current vaccines and immunisation measures. Finally, the versatility and potency of nucleic acid-based drugs make them drug candidates for use in seasonal or pandemic influenza. A new challenge became evident with avian influenza A/H5N1, which has caused over 300 human infections, with an approximate 50% mortality rate. The virus is novel for human, and the lack of immunity qualifies it for a possible pandemic influenza virus. Additionally, wild migratory birds are spreading the virus across large geographic areas. Newer clade 2 A/H5N1 influenza viruses have begun to emerge.
Interesting results were obtained in developing vaccines against the coronavirus, agent of severe acute respiratory syndrome (SARS), using nucleic acid-based immunomodulators and cDNA constructs encoding the structural antigens. Also the SARS DNA vaccines inducing human neutralising antibodies are under investigation. The development of a synthetic peptide vaccine to treat chronic hepatitis C is of great interest, as worldwide only half of 170 million patients do respond to interferon/ribavarin treatment. As the Japanese encephalitis is still endemic in Japan and other regions of Asia, the next generation of vaccine against JEV, safe and immunogenic, is promising to reduce the major cause of children encephalitis in South and South-East Asia.
Genetic vaccination is predicted to have a promising future. Post-exposure DNA vaccination protects mice against rabies virus and investigations of the efficacy of HIV-1 DNA vaccines in humans support this approach. Despite unlimited efforts and important financial resources given to multiple projects to develop a vaccine against the human immunodeficiency virus disease AIDS, the results obtained remain elusive. Pre-clinical and clinical studies demonstrated that neutralising antibodies are protective and that ADCC could play a role in controlling acute virus infection. Some immunisation protocols have revealed the inducing of HIV specific humoral and cellular responses in human vaccines. A lot of interesting data is accumulated by several groups, but in the presence of a virus which is genetically extremely variable, and in the absence of biological correlates of protection and of a reliable animal model, the development of a vaccine against the human immunodeficiency viruses remains a formidable challenge.
Confirmed research trends in paediatric vaccination consist in the development of combination vaccines with aim to immunise against several diseases and to reduce the number of shots required. Currently, various childhood combination vaccines are under investigation or already licensed. For example, to diphtheria-tetanus-accellular pertussis antigens were added Haemophilus influenzae type b glycoconjugate vaccine, hepatitis B and inactivated polio vaccines. It was reported that such combination vaccines elicit very high immune responses for all components, with exception of Hib, for which a decrease of antibodies is noted, probably due to interference between vaccine components and glycoconjugates. The combination of components having similar characteristics is more compatible to avoid eventual interference problems. However, it was reported that the new liquid hexavalent vaccine containing diphtheria, tetanus, two-component acellular pertussis, inactivated polio virus, Haemophilus influenzae type b and hepatitis B virus antigens, resulted in protective immune responses to all antigens. The immune response elicited by the novel formulation of combined hepatitis A and B vaccine, compares well with sero-responses obtained after administration of monovalent vaccines. The new seven-valent pneumococcal conjugate vaccine, has proven efficacy and safety against pneumococcal diseases and otitis in infants, and elicited a significant antibody response to each pneumococcal vaccine serotype. It is predicted that this multivalent vaccine will play an important role in paediatric prevention of invasive and noninvasive pneumococcal diseases. Streptococcus pneumoniae is a leading cause of pneumococcal infections and accounts, respectively, for up to 40% and 50% of all cases of bacterial meningitis and bacterial otitis. The task for the future paediatric immunisation is to develop multivalent combination vaccines. A systematic analysis of multiple genomes to understand the complexity of antigens variation in pathogens, as well as the molecular epidemiology of infections, is fundamental to develop a broad vaccine with selected combination of antigens from designated species of microbes. In this respect, the reverse vaccinology, an in silico based system to analyse genetic information of antigens, has proved to be powerful tool, especially, in the discovery of vaccines for group B meningococcus and group B streptococcus.
In search of vaccine efficacy, a significant attention is given to the concept of mucosal immunisation. With the progressing knowledge of mucosal immunoregulation, on new technologies for vaccine delivery, immunomodulation and immunopotentiators, the immunisation of mucosal surfaces has become very attractive. To induce immune responses, most vaccines, when administered mucosally, need the use of strong, non-toxic adjuvants. The new generation of cholera toxin and Escherichia coli enterotoxin are non-toxic and powerful mucosal adjuvants, being able to elicit high immune responses. Also, the recent research on oral plant-based vaccines is of great interest. Plants are being used for production of bio-medical components, including prophylactic vaccines and therapeutic antibodies.
Several research investigators reported a substantial progress in anti-cancer and disease therapeutic vaccines, with the discovery and development of antigens for tumor immunotherapy. Of major importance is the identification of tumor-associated antigens for the development of tumor-specific therapeutic and prophylactic vaccines. The designed mimotopes, for cancer immunotherapy, for clinical application, are under investigation, and validating the concept. Studies in patients with therapeutic candidate vaccines against melanoma and colorectal cancer and on human papilloma virus (HPV) in pre-invasive and invasive cervical cancer provides incentives for clinical applications of potential immunotherapy. Prophylactic HPV vaccines comprising HPV 16/18 virus-like particles (VLPs) have com-pleted late stage clinical trials in women age 15-25 years. HPV 16/18 is responsible for approximately 70% of cervical cancers and pre-malignant neoplasia worldwide. Clinical trials have demonstrated 95-100% efficacy against persistent HPV 16/18 infection and associated CIN, with some preliminary evidence of cross protection against other oncogenic types. These trials have shown immunity to be sustained for up to 5 years. Another effective candidate vaccine against oncogenic HPV types alone (16, 18, 45 and 31) also ensure immunogenicity and safety. Both vaccine candidates prevent HPV infection and HPV cervical disease at 90-100% efficacy. Phase 2/3 clinical trials of vaccines against breast cancer, for leukemia and lung cancer, are progressing satisfactorily. Site-specific peptide vaccines for immunotherapy and immunisation against cancer, infectious diseases, chronic diseases, and for veterinary applications using the core technologies, carry great expectations. For example, the in vitro and in vivo studies in macaques support the potential efficacy and safety of a vaccine as an immunotherapy for the prevention and stabilization of Alzheimer's disease. The vaccine is highly immunogenic in two non-human primate species. Immunogenicity in human populations is predicted.
The WCVII 2006, held in Canada, confirmed that we are in new era of vaccinology, with sophisticated genetic technologies to produce immunogenic safe vaccines, immune therapeutics and modern immunisation strategies, in preventing and controlling diseases.
